Study guide

17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting

BCEMP Board Certified Emergency Medicine Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals

1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access

2 Chapter 2: Cardiac Arrest and Dysrhythmias

2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)

3 Chapter 3: Shock and Hemodynamic Resuscitation

3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols

4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)

4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation

5 Chapter 5: Neurocritical Care and Neurologic Emergencies

5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies

6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure

6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure

7 Chapter 7: Pulmonary and Allergic Emergencies

7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols

8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses

8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)

9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes

9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST

10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology

10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome

11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies

11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT

12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship

12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics

13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics

13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH

14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness

14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles

15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation

15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED

16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery

16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling

17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry

17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose

18 Chapter 18: Special Populations, Medication Access, and Professional Practice

18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)

17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting

Key Takeaways Explain This Topic AI

Suspected variceal bleeding needs octreotide (50 mcg IV bolus, then 50 mcg/h for 2 to 5 days) and ceftriaxone 1 g daily for up to 7 days, with transfusion to a hemoglobin target of about 7 g/dL.

In HALT-IT (2020), tranexamic acid did not reduce death from GI bleeding and increased venous thromboembolism, so it is not used routinely.

Spontaneous bacterial peritonitis is treated with a third-generation cephalosporin, plus albumin 1.5 g/kg on day 1 and 1 g/kg on day 3 when kidney or liver markers are high.

Terlipressin for hepatorenal syndrome carries a boxed warning for serious or fatal respiratory failure and should not be started when SpO2 is below 90%.

In the WATERFALL trial (2022), aggressive fluids in acute pancreatitis caused more fluid overload without better outcomes, so moderate goal-directed resuscitation is preferred.

Last updated: October 2026

17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting

Note

Exam scope: 2025 outline subtopics 2B3 (Gastroenterology, Genitourinary and Obstetrics) and 2B6 (Nephrology and Hepatology). Anticoagulant reversal for bleeding patients is covered in Section 10.1, and acetaminophen-induced liver failure in Section 8.2.

  • Acute Upper GI Bleeding
  • Risk Stratification and General Care

The Glasgow-Blatchford score uses BUN, hemoglobin, systolic blood pressure, heart rate, melena, syncope, liver disease and heart failure. ACG (2021) suggests that patients with a score of 0 or 1 can be managed as outpatients.

Transfusion: restrictive, with a hemoglobin threshold of 7 g/dL (about 8 g/dL with cardiovascular disease).

Anticoagulants and antiplatelets: hold and reverse according to bleeding severity (Section 10.1). Aspirin for secondary prevention is usually resumed soon after hemostasis.

Tranexamic acid: not recommended. In HALT-IT (2020, about 12,000 patients), TXA did not reduce death from bleeding and increased venous thromboembolism (0.8% vs. 0.4%) and seizures.

Nonvariceal Bleeding (Peptic Ulcer)

Intervention Evidence summary

PPI before endoscopy Reduces high-risk findings at endoscopy but not rebleeding, surgery or death. ACG 2021 makes no recommendation for or against it, and it is often given while awaiting endoscopy

High-dose PPI after endoscopic hemostasis Recommended for 3 days: for example, pantoprazole 80 mg IV bolus then 8 mg/h, or intermittent high-dose IV doses at least twice daily

Erythromycin before endoscopy 250 mg IV 30 to 120 minutes before endoscopy improves the view by emptying the stomach (suggested by ACG); check QTc and interactions

  • H. pylori testing Test and treat to prevent rebleeding
  • Variceal Bleeding in Cirrhosis

Suspect varices in any patient with cirrhosis and GI bleeding. Treatment starts before endoscopy:

Vasoactive therapy: octreotide 50 mcg IV bolus, then 50 mcg/h , continued for 2 to 5 days after endoscopic therapy. Terlipressin is used outside the United States for this indication.

Antibiotic prophylaxis: ceftriaxone 1 g IV daily for up to 7 days . Infection is common after variceal bleeding, and prophylaxis reduces infection, rebleeding and death.

Restrictive transfusion: a hemoglobin target of about 7 g/dL. Over-transfusion raises portal pressure and increases rebleeding.

Endoscopic band ligation within 12 hours , followed by nonselective beta-blockers once the patient is stable.

INR is a poor guide to bleeding risk in cirrhosis because both procoagulant and anticoagulant factors fall. Do not give fresh frozen plasma just to correct the INR.

  • Complications of Cirrhosis
  • Hepatic Encephalopathy

Look for and treat precipitants: GI bleeding, infection, constipation, dehydration, electrolyte disturbance, and sedatives or opioids.

Lactulose 25 mL every 1 to 2 hours until at least two soft bowel movements, then titrate to 2 to 3 soft bowel movements a day . Give it by nasogastric tube or as an enema if the patient cannot swallow safely.

Polyethylene glycol 4 L over 4 hours resolved encephalopathy faster than lactulose in the HELP trial (2014).

Rifaximin 550 mg twice daily is added to lactulose to prevent recurrence.

Avoid benzodiazepines, which worsen encephalopathy, except for alcohol withdrawal.

Spontaneous Bacterial Peritonitis (SBP)

The diagnosis is an ascitic fluid neutrophil count of 250 cells/mm3 or more .

Antibiotics: a third-generation cephalosporin such as cefotaxime 2 g IV every 8 hours or ceftriaxone. Use broader therapy for hospital-acquired infection or recent antibiotic exposure.

Albumin: 1.5 g/kg within 6 hours of diagnosis and 1 g/kg on day 3, given when creatinine is above 1 mg/dL, BUN is above 30 mg/dL or bilirubin is above 4 mg/dL. Albumin reduces kidney failure and death.

Worked example: an 80-kg patient with a creatinine of 1.6 mg/dL needs 120 g of albumin on day 1 and 80 g on day 3.

After large-volume paracentesis (more than 5 L), give 6 to 8 g of albumin per liter removed.

Hepatorenal Syndrome (HRS-AKI)

After stopping diuretics and nephrotoxins and giving albumin (1 g/kg/day for 2 days, maximum 100 g/day), HRS-AKI is treated with a vasoconstrictor plus albumin.

Terlipressin (approved in the US in 2022):

0.85 mg IV every 6 hours on days 1 to 3.

On day 4, increase to 1.7 mg every 6 hours if creatinine has fallen less than 30%, and stop if creatinine is at or above baseline.

Continue until 24 hours after two creatinine values of 1.5 mg/dL or less, taken at least 2 hours apart, or for a maximum of 14 days.

Warning

Terlipressin carries a boxed warning for serious or fatal respiratory failure . Do not start it when SpO2 is below 90%, and monitor oxygenation throughout. Patients who are volume overloaded or have grade 3 acute-on-chronic liver failure are at highest risk, and those with a creatinine of 5 mg/dL or more are unlikely to benefit.

Norepinephrine plus albumin is an ICU alternative. Midodrine with octreotide is weaker and is used only when the other options cannot be.

Alcohol-Associated Hepatitis

For severe disease (Maddrey discriminant function 32 or higher, or MELD above 20) without active infection or GI bleeding, prednisolone 40 mg daily for 28 days is an option. A Lille score of 0.45 or higher on day 7 indicates nonresponse, and steroids are stopped. Prednisolone is used rather than prednisone because it does not need hepatic activation. Screen for infection first.

Acute Liver Failure Not Caused by Acetaminophen

IV N-acetylcysteine improved transplant-free survival in patients with early-grade (I to II) encephalopathy from non-acetaminophen acute liver failure (Lee, 2009). Contact a transplant center early.

Drug Dosing in Cirrhosis

Acetaminophen is the preferred analgesic, usually limited to 2 g/day .

Avoid NSAIDs , which cause kidney injury, GI bleeding and diuretic resistance.

Use opioids cautiously at reduced doses and longer intervals. Hydromorphone or fentanyl are often preferred over morphine; avoid meperidine and codeine.

Creatinine-based equations overestimate kidney function in patients with low muscle mass.

Acute Pancreatitis

Fluids: in WATERFALL (2022), aggressive resuscitation (20 mL/kg bolus, then 3 mL/kg/h) caused more fluid overload (20.5% vs. 6.3%) than moderate resuscitation without reducing severe disease. The trial was stopped early. The moderate approach is 10 mL/kg only if the patient is hypovolemic, then 1.5 mL/kg/h, adjusted to clinical response. Lactated Ringer's is commonly preferred.

Antibiotics: not given as prophylaxis. Use them only for documented infection or suspected infected necrosis.

Analgesia: opioids are acceptable and do not worsen outcomes. Multimodal regimens reduce opioid needs.

Feeding: start oral feeding early, within 24 to 48 hours, as tolerated.

Hypertriglyceridemia above about 1,000 mg/dL: insulin infusion with dextrose, or plasmapheresis in selected cases.

Nausea, Vomiting and Cannabinoid Hyperemesis

  • Agent Key cautions
  • Ondansetron QT prolongation; the maximum single IV dose is 16 mg (the 32 mg IV dose was withdrawn in 2012)

Metoclopramide Akathisia (infuse over 15 minutes to reduce it), dystonia; boxed warning for tardive dyskinesia with long-term use

  • Prochlorperazine Akathisia and dystonia; also effective for migraine
  • Droperidol Boxed warning for QT prolongation; very effective at low doses (0.625 to 1.25 mg)

Promethazine Severe tissue injury with IV use (Section 16.2); boxed warning against use in children under 2 years

Cannabinoid hyperemesis syndrome (cyclic vomiting with heavy cannabis use, often relieved by hot showers) responds poorly to ondansetron. In the HaVOC trial (2021), haloperidol 0.05 to 0.1 mg/kg IV relieved symptoms better than ondansetron 8 mg. Topical capsaicin 0.1% to the abdomen and droperidol are alternatives. Stopping cannabis is the only lasting cure.

Esophageal food impaction: glucagon 1 mg IV rarely works and must not delay endoscopy. A patient who cannot swallow saliva needs urgent endoscopy.